Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy
S. Malathi, Valappil Sisila, Vijayapoopathi Singaravel, Nandakumar Venkatesan, Iqbal Pakrudheen, Rajesh Kumar Dhanaraj, Niraikulam Ayyadurai, V. Bhuvarahamurthy, S. Narayana Kalkura
Abstract
NIODVC (cetuximab-conjugated doxorubicin and vitexin loaded niosome) proves effective for targeted breast cancer therapy. Enhanced cytotoxicity, cellular uptake, and gene downregulation show promise.
Topics & Concepts
DoxorubicinNiosomeVitexinCetuximabBreast cancerCytotoxicityDownregulation and upregulationCancer researchEpidermal growth factor receptorMedicineCancerOncologyChemotherapyChemistryInternal medicineColorectal cancerGeneIn vitroBiochemistryMembraneFlavonoidAntioxidantVesicleNanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryHER2/EGFR in Cancer Research